secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2026-07-23T20:29:00+00:00
Accession:  0001099800-26-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q2 sales up 13.6% to $1.74B; raises full-year sales and TAVR guidance
-----------------------------------------------------------------------------

- Q2 sales $1.74B (+13.6% YoY); adjusted EPS $0.78; gross margin 77.5%.
- TAVR sales $1.26B (+11.3% YoY); TMTT sales $195.9M (+47.3% YoY); Surgical $284M (+6.5% YoY).
- Raised FY constant currency sales growth guidance to 10-11% (from 9-11%); TAVR growth to 8-9% (from 7-9%).
- Reaffirmed adjusted EPS guidance $2.95-$3.05; Q3 guidance: sales $1.63-$1.71B, adj EPS $0.71-$0.77.
- Cash $2.9B, debt $600M; $1.5B remaining share repurchase authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/0001099800-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ew-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001099800-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer